JP Morgan maintains TransMedics Group at Neutral, raises price target to $85 from $73
JP Morgan kept its 'Neutral' rating on TransMedics Group but raised its price target to $85 from $73, a 16.4% increase. The new target suggests a 3.7% downside from the Nov 6 close of $88.24. Other recent analyst targets for the company range from $110 to $120.
How this was made

The 30-second read
Why it matters
The target increase may attract buyers seeking upside, but the effect is modest without a catalyst.
Market read
A modest analyst upgrade that could generate short‑term buying pressure.
What to watch
Potential regulatory or reimbursement risks not addressed in the note.
Background
Analyst price target updates are routine but can influence short‑term trading.
Market effects
May lift sentiment in the medical device sector.
Limited to US markets where TMED trades.
Low; impact confined to the company and its niche sector.
Counterpoint
Target raises can be premature; price may already reflect optimism.
Key entities
- analystJP Morgan
Provided the price target upgrade.
- companyTransMedics Group
Subject of the price target change.



